“We believe patients with lung disease deserve better options. We aim to create better pharmaceutical treatment options for life-threatening lung issues.” Brian Windsor, CEO
Lung Therapeutics, Inc., a clinical stage pharmaceutical company formed to leverage leading research in lung injury and disease due to fibrosis, is pursuing niche, orphan drug indications for which there is no current effective therapeutic option. The company is pioneering the development and commercialization of safe, effective drugs for the non-surgical treatment of fibrosis in and around the lungs: LTI-03 for Idiopathic Pulmonary Fibrosis and LTI-01 for Pleural Effusion with Loculation. For more information, visit
lungtx.com.
